Dr Sonali P Majmudar, MD | |
1585 Barrington Rd, Suite 503, Hoffman Estates, IL 60169-1090 | |
(847) 781-3002 | |
(847) 781-3694 |
Full Name | Dr Sonali P Majmudar |
---|---|
Gender | Female |
Speciality | Allergy/immunology |
Experience | 29 Years |
Location | 1585 Barrington Rd, Hoffman Estates, Illinois |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1528164118 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207K00000X | Allergy & Immunology | 036-097458 (Illinois) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Wyandot Memorial Hospital | Upper sandusky, OH | Hospital |
St Alexius Medical Center | Hoffman estates, IL | Hospital |
Mailing Address | Practice Location Address |
---|---|
Dr Sonali P Majmudar, MD 1585 Barrington Rd, Suite 503, Hoffman Estates, IL 60169-1090 Ph: (847) 781-3002 | Dr Sonali P Majmudar, MD 1585 Barrington Rd, Suite 503, Hoffman Estates, IL 60169-1090 Ph: (847) 781-3002 |
News Archive
When you ask patients and colleagues what makes Lakeridge Health's Nurse Practitioner (NP) Michelle Acorn special a common thread quickly emerges 'her dedication to the health and well-being of her patients and her wealth of knowledge'.
A study has revealed a simulation that incorporates the hand's skin, muscles, bones, tendons and joints, which will be valuable for the development of biologically-inspired robotic hands.
It is well-known that patients who undergo Fontan surgery slowly develop liver fibrosis for years post-operatively. In the past decade, these incidences have been steadily increasing and this is due partly to the need for an accurate diagnostic method.
The Stem Cell Transplant Program at the University of Virginia Cancer Center has received international accreditation for its use of stem cells and bone marrow to treat patients with blood cancers.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 3 days ago
Mark Miller, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1000 Grand Canyon Pkwy Ste 301, Hoffman Estates, IL 60169 Phone: 847-352-2822 | |
Anne Grace Szpindor, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1585 N Barrington Rd, Ste 606, Hoffman Estates, IL 60169 Phone: 847-310-8844 Fax: 847-310-9224 |